Crew Capital Management Ltd. Buys New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Crew Capital Management Ltd. bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 375 shares of the biopharmaceutical company’s stock, valued at approximately $329,000.

Other large investors have also modified their holdings of the company. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. Fortitude Family Office LLC purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $31,000. MCF Advisors LLC boosted its position in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the period. Criterion Capital Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $37,000. Finally, Sutton Wealth Advisors Inc. lifted its position in shares of Regeneron Pharmaceuticals by 38.2% during the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 13 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling

In other news, Director Bonnie L. Bassler sold 827 shares of the company’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at $1,325,338. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,325,338. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the sale, the executive vice president now directly owns 13,789 shares in the company, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,022 shares of company stock valued at $10,552,991. Insiders own 8.83% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on REGN. Royal Bank of Canada reiterated an “outperform” rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. UBS Group lifted their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. BMO Capital Markets lifted their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Sanford C. Bernstein began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price target on the stock. Finally, StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 20th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $977.77.

Regeneron Pharmaceuticals Price Performance

REGN stock traded up $9.28 during trading on Monday, reaching $892.48. 369,878 shares of the company were exchanged, compared to its average volume of 489,599. The company has a market cap of $97.96 billion, a P/E ratio of 25.42, a PEG ratio of 2.54 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33. The stock’s 50 day moving average price is $948.00 and its 200 day moving average price is $894.45. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. The firm had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm’s revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $10.96 earnings per share. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.